Axial Spondyloarthritis (axSpA) Treatment Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Axial Spondyloarthritis (axSpA) Treatment Market is segmented By Drug Class (TNF Inhibitors (Infliximab, Etanercept), IL-17 Inhibitors (Secukinumab, Ixekizumab), Other Classes, By Route of Administration (Injectable, Oral), By Molecule Type (Small Molecules, Biologics), By Disease Type (Radiographic AxSpA (Ankylosing Spondylitis), Non-Radiographic AxSpA), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned.

Axial Spondyloarthritis (axSpA) Treatment Market is segmented By Drug Class (TNF Inhibitors (Infliximab, Etanercept), IL-17 Inhibitors (Secukinumab, I....

Axial Spondyloarthritis (axSpA) Treatment Market Size

Market Size in USD

CAGR7.5%

Study Period	2024 - 2031
Base Year of Estimation	2023
CAGR	7.5%
Market Concentration	High
Major Players	AbbVie Inc., Novartis AG, Pfizer Inc., UCB Pharma, Eli Lilly and Company

*Disclaimer: Major players are listed in no particular order.

*Source: Coherent Market Insights

Want to purchase customized report?
please let us know !

Axial Spondyloarthritis (axSpA) Treatment Market Analysis

The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031. Increased prevalence of axSpA and rising population are major drivers responsible for growth of this market. Additionally, development and launch of novel biologic therapies for axSpA treatment such as IL-23 and IL-17 inhibitors have boosted the market growth over the past years.

Axial Spondyloarthritis (axSpA) Treatment Market Report Snapshots

Buy Now